Where to drawthe boundaries for prenatal carrier screening

JAMA - Journal of the American Medical Association

Volumn 316, Issue 7, 2016, Pages 717-719

  Grody, Wayne W ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATAXIA TELANGIECTASIA; CYSTIC FIBROSIS; DISEASE SEVERITY; DNA SEQUENCE; ETHNICITY; FAMILY HISTORY; GENE MUTATION; GENE SEQUENCE; GENETIC DISORDER; HETEROZYGOTE; HUMAN; MALIGNANT NEOPLASTIC DISEASE; PREGNANCY TERMINATION; PRENATAL DIAGNOSIS; PRENATAL SCREENING; PRIORITY JOURNAL; REVIEW; X CHROMOSOME RECESSIVE DISORDER; GENETIC SCREENING;

CYSTIC FIBROSIS; GENETIC TESTING; HUMANS; PRENATAL DIAGNOSIS;

EID: 84984830666     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2016.10888     Document Type: Review

References (12)

1. Haque IS, Lazarin GA, Kang HP, et al. Modeled fetal risk of genetic diseases identified by expanded carrier screening. JAMA. doi:10.1001/jama.2016.11139.
2. Lee H, Deignan JL, Dorrani N, et al. Clinical exome sequencing for genetic identification of rare Mendelian disorders. JAMA. 2014;312(18):1880-1887.
3. Yang Y, Muzny DM, Xia F, et al. Molecular findings among patients referred for clinical whole-exome sequencing. JAMA. 2014;312(18): 1870-1879.
4. GrodyWW, Cutting GR, Klinger KW, Richards CS, Watson MS, Desnick RJ; Subcommittee on Cystic Fibrosis Screening, Accreditation of Genetic Services Committee, American College of Medical Genetics. Laboratory standards and guidelines for population-based cystic fibrosis carrier screening. Genet Med. 2001;3(2):149-154.
5. Gross SJ, Pletcher BA, Monaghan KG; Professional Practice and Guidelines Committee. Carrier screening in individuals of Ashkenazi Jewish descent. Genet Med. 2008;10(1):54-56.
6. American College of Obstetricians and Gynecologists Committee on Genetics. ACOG Committee opinion No. 469: carrier screening for fragile X syndrome. Obstet Gynecol. 2010;116(4): 1008-1010.
7. GrodyWW, Thompson BH, Gregg AR, et al. ACMG position statement on prenatal/preconception expanded carrier screening. Genet Med. 2013;15(6):482-483.
8. GrodyWW, Cutting GR,Watson MS. The cystic fibrosis mutation "arms race": when less is more. Genet Med. 2007;9(11):739-744.
9. Gallant NM, Leydiker K, Tang H, et al. Biochemical, molecular, and clinical characteristics of children with short chain acyl-CoA dehydrogenase deficiency detected by newborn screening in California. Mol GenetMetab. 2012;106 (1):55-61.
10. GrodyWW. Expanded carrier screening and the law of unintended consequences: from cystic fibrosis to fragile X. Genet Med. 2011;13(12):996-997.
11. Richards S, Aziz N, Bale S, et al; ACMG Laboratory Quality Assurance Committee. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17(5):405-424.
12. Edwards JG, Feldman G, Goldberg J, et al. Expanded carrier screening in reproductive medicine-points to consider: a joint statement of the American College of Medical Genetics and Genomics, American College of Obstetricians and Gynecologists, National Society of Genetic Counselors, Perinatal Quality Foundation, and Society forMaternal-Fetal Medicine. Obstet Gynecol. 2015;125(3):653-662.